Story
Viatris Sues Novo Nordisk in Bid to Launch Generic Wegovy
Summary
Generic drugmaker Viatris has filed a lawsuit against Novo Nordisk, seeking a federal court ruling that its proposed version of the weight-loss drug Wegovy does not violate patents on the injection pen technology.
Viatris Inc. has filed a lawsuit against Novo Nordisk, seeking a U.S. federal court to declare that its proposed generic version of the popular weight-loss drug Wegovy would not infringe on the Danish drugmaker's patents. The legal action represents a proactive step by the generic manufacturer to clear a potential barrier to market entry.
The Legal Challenge
The complaint was filed in Delaware federal court on Thursday by Mylan Pharmaceuticals, a unit of Viatris, according to court documents. Viatris is asking the court for a declaratory judgment of non-infringement regarding a specific Novo Nordisk patent.
The patent in question covers the method of administering the single-dose Wegovy injection pens, a key component of the product's delivery system, rather than the drug's core active ingredient.
High Stakes for a Blockbuster Drug
AdThe legal battle targets one of the most lucrative drug franchises in the pharmaceutical industry. Novo Nordisk's semaglutide-based medications, which include Wegovy and the diabetes drug Ozempic, generated nearly $31 billion in revenue last year, according to company reports.
This lawsuit is significant for investors as it signals the beginning of legal maneuvers that could eventually lead to lower-cost alternatives. However, the primary barrier to generic competition remains intact, as Novo Nordisk's core patents protecting the active ingredient semaglutide do not expire in the U.S. until 2032.
Context and Precedent
Challenging patents is a common strategy for generic drug companies aiming to launch lower-cost alternatives before a brand-name drug's market exclusivity ends. According to reports, Novo Nordisk has previously engaged in and settled patent lawsuits with Mylan and other drugmakers over proposed generics for its semaglutide products, which could set a precedent for the current dispute.
Read next
More on Stocks
Oura IPO Sees Demand Outstrip Supply by Four Times, Report Says
The health and fitness technology company's initial public offering is attracting significant investor interest, with orders reportedly reaching four times the shares available as it seeks to raise up to $2.2 billion.
Insurance Firm Fidelis Partnership Files for US Initial Public Offering
Insurance firm TFP Group, which operates as the Fidelis Partnership, has filed for an initial public offering in the U.S., setting the stage for a public listing amid a challenging market for new issues.
S&P Cuts Cable One's Credit Rating to 'B+' on Fierce Broadband Competition
S&P Global Ratings has lowered Cable One's issuer credit rating, citing intense pressure from fiber and fixed wireless rivals that is eroding the company's profitability and market share.
Mirum Pharma Gains as Investors Await FDA Ruling on Rare Disease Drug
Shares of Mirum Pharmaceuticals rose in Monday trading as the company approaches a key regulatory decision from the U.S. Food and Drug Administration for its drug candidate, zilurgisertib, which treats an ultra-rare bone disease.